Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 619 results
Found 619 results.


Henrich TJ, McLaren PJ, Rao SSP, et al. "Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study." Open Forum Infect Dis. 2014;1(1):ofu018.
Leger PD, Johnson DH, Robbins GK, et al. "Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384." J. Neurovirol.. 2014;20(3):304-8.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Kojic EMilunka, Kang M, Cespedes MS, et al. "Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women." Clin. Infect. Dis.. 2014;59(1):127-35.
Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW. "Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy." PLoS ONE. 2014;9(3):e92118.
Sacktor N, Miyahara S, Evans S, et al. "Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment." J. Neurovirol.. 2014;20(6):620-6.
Erlandson KMace, Kitch D, Tierney C, et al. "Impact of randomized antiretroviral therapy initiation on glucose metabolism." AIDS. 2014;28(10):1451-61.
Godfrey C, Schouten JT, Swindells S. "Implementation of HIV-related clinical research in the international setting." J. Acquir. Immune Defic. Syndr.. 2014;65 Suppl 1:S1-2.
Boswell KL, Paris R, Boritz E, et al. "Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection." PLoS Pathog.. 2014;10(1):e1003853.
Boltz VF, Bao Y, Lockman S, et al. "Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP." J. Infect. Dis.. 2014;209(5):703-10.
Castillo-Mancilla JR, Cohn SE, Krishnan S, et al. "Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials." HIV Clin Trials. 2014;15(1):14-26.
Van Epps P, Matining RM, Tassiopoulos K, et al. "Older age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy." PLoS ONE. 2014;9(9):e107064.
Smith KY, Tierney C, Mollan K, et al. "Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine." Clin. Infect. Dis.. 2014;58(4):555-63.
Dooley KE, Luetkemeyer AF, Park J-G, et al. "Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin." Antimicrob. Agents Chemother.. 2014;58(9):5245-52.
Marks KM, Kitch D, Chung RT, et al. "Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239." J. Acquir. Immune Defic. Syndr.. 2014;65(3):345-9.
Bruggeman LA, O'Toole JF, Ross MD, et al. "Plasma apolipoprotein L1 levels do not correlate with CKD." J. Am. Soc. Nephrol.. 2014;25(3):634-44.
Shivakoti R, Gupte N, Yang W-T, et al. "Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy." Nutrients. 2014;6(11):5061-78.
Asmelash A, Zheng Y, Kaloustian KWools, et al. "Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa." BMC Infect. Dis.. 2014;14:331.
Kalayjian RC, Wu K, Evans S, et al. "Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2014;67(1):30-5.
Safren SA, Biello KB, Smeaton L, et al. "Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial." PLoS ONE. 2014;9(8):e104178.
Jacobson JM, Wang H, Bordi R, et al. "A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2014;66(4):399-406.
Weinberg A, Bosch R, Bennett K, et al. "Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS." J. Acquir. Immune Defic. Syndr.. 2014;66(1):25-32.
Li JZ, Heisey A, Ahmed H, et al. "Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study." AIDS. 2014;28(18):2649-57.
F Romo T, Smeaton LM, Campbell TB, et al. "Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175)." HIV Clin Trials. 2014;15(6):246-60.
Mwafongo A, Nkanaunena K, Zheng Y, et al. "Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine." AIDS. 2014;28(8):1135-42.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Sulkowski MS, Kang M, Matining R, et al. "Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study." J. Infect. Dis.. 2014;209(5):658-67.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.